Evidence-Based Ways to Improve Your FibroScan (VCTE) Score

What a FibroScan Number Does and Does Not Mean

Vibration-controlled transient elastography (VCTE, commonly called FibroScan) measures how quickly a shear wave travels through the liver. The result is reported as liver stiffness in kilopascals (kPa). Fibrosis can make the liver stiffer, but stiffness is not a biopsy and is not specific to scar tissue (AASLD guidance).

Interpretation depends on the suspected liver disease and the purpose of the test. Thresholds used to rule out advanced fibrosis are not necessarily the same as thresholds used to rule it in. Results also differ across MASLD, alcohol-related liver disease, viral hepatitis, cholestatic disease, and other conditions. A report should therefore be read with blood tests, history, imaging, and sometimes a second noninvasive test or biopsy.

First Check Whether the Tests Are Comparable

Before treating a change as true improvement or progression, ask:

• Was the patient fasting according to the testing center's protocol?
• Was the same probe type used, and was it appropriate for body size?
• Were there enough valid measurements and acceptable variability?
• Was there acute hepatitis, bile-duct obstruction, heart failure/congestion, or another transient influence?
• Were the tests performed for the same liver diagnosis?

A small kPa change can reflect measurement variation or changing inflammation rather than new scar formation or regression. This is why “how do I lower the number before my test?” is the wrong question. The goal is lower liver risk over time.

What Can Improve Liver Risk in MASLD or MASH?

Sustained weight loss when excess weight is present

In a prospective lifestyle study of people with NASH, greater weight loss was associated with better histology; the strongest results occurred among participants who lost at least 10% of body weight. That does not make 10% a universal prescription. A safe, maintainable target depends on starting weight, nutrition, medications, comorbidities, and whether unintentional weight loss is present.

Physical activity and cardiometabolic treatment

Exercise can reduce liver fat and improve cardiometabolic health even when the scale changes modestly. Diabetes treatment, lipid management, blood-pressure control, sleep-apnea care, and smoking cessation address the cardiovascular risk that drives much of the long-term burden in MASLD. A Mediterranean-style eating pattern is one evidence-supported option, but no single named diet is required.

Alcohol decisions based on diagnosis and risk

Alcohol can worsen several liver diseases, but a single reduction rule is not appropriate for every patient. People with advanced fibrosis, cirrhosis, alcohol-related liver disease, or medication interactions may be advised to avoid it entirely. The amount, pattern, and diagnosis should be discussed directly rather than inferred from one FibroScan value.

Where GLP-1 Therapy Fits

The evidence has changed. In August 2025, the FDA added an indication for Wegovy (semaglutide) in adults with noncirrhotic MASH and moderate-to-advanced fibrosis (F2-F3), based on interim results from the phase 3 ESSENCE trial. In that trial, semaglutide improved liver-histology endpoints and produced more weight loss than placebo.

That does not mean any elevated FibroScan score is an indication for semaglutide. Eligibility depends on the labeled diagnosis, fibrosis stage, contraindications, and the product's current prescribing information. Earlier semaglutide studies in different populations should not be substituted for the current indication.

Where Resmetirom Fits

Rezdiffra (resmetirom) is FDA approved, under accelerated approval, with diet and exercise for adults with noncirrhotic MASH and F2-F3 fibrosis (current label). MAESTRO-NASH demonstrated higher rates of MASH resolution and fibrosis improvement on biopsy than placebo at 52 weeks.

Resmetirom is not a general treatment for “high FibroScan.” Current labeling includes weight-based dosing, liver-injury and gallbladder warnings, and important interactions with certain statins and CYP2C8/OATP1B1/OATP1B3 modifiers. Its effect should be assessed through the treating clinician's broader MASH plan, not a promise that kPa will fall by a fixed amount.

How Often Should FibroScan Be Repeated?

There is no universal 3-, 6-, or 12-month schedule. Timing depends on baseline risk, diagnosis, treatment, prior result quality, and whether the answer would change care. Repeating too soon can turn normal test variability into false reassurance or unnecessary alarm. A clinician may instead use FIB-4, ELF, MRI-based elastography, imaging, labs, or biopsy when those tools better answer the clinical question.

Questions to Ask About a New Result

1. Was the exam technically reliable?
2. Which liver disease and cutoff framework is being used?
3. Could inflammation, congestion, cholestasis, or a meal have influenced the value?
4. Does the result agree with platelets, AST/ALT, FIB-4, imaging, and symptoms?
5. What change in treatment or follow-up would this result actually justify?